Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

Orazio Caffo, Cinzia Ortega, Franco Nolè, Donatello Gasparro, Claudia Mucciarini, Michele Aieta, Vittorina Zagonel, Roberto Iacovelli, Ugo De Giorgi, Gaetano Facchini, Antonello Veccia, Erica Palesandro, Elena Verri, Sebastiano Buti, Giorgia Razzini, Giovanni Bozza, Marco Maruzzo, Chiara Ciccarese, Giuseppe Schepisi, Sabrina RossettiFrancesca Maines, Stefania Kinspergher, Lucia Fratino, Paola Ermacora, Maurizio Nicodemo, Monica Giordano, Donata Sartori, Daniela Scapoli, Roberto Sabbatini, Giovanni Lo Re, Franco Morelli, Alessandro D'Angelo, Isabella Vittimberga, Paolo Lippe, Francesco Carrozza, Caterina Messina, Luca Galli, Francesca Valcamonico, Camillo Porta, Giovanni Pappagallo, Massimo Aglietta

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences